看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 10.9x - 12.0x | 11.4x |
| Selected Fwd EBITDA Multiple | 9.9x - 10.9x | 10.4x |
| Fair Value | $141.10 - $161.96 | $151.53 |
| Upside | -20.3% - -8.5% | -14.4% |
| Benchmarks | Ticker | Full Ticker |
| Labcorp Holdings Inc. | LH | NYSE:LH |
| Enzo Biochem, Inc. | ENZB | OTCPK:ENZB |
| OPKO Health, Inc. | OPK | NasdaqGS:OPK |
| Interpace Biosciences, Inc. | IDXG | OTCPK:IDXG |
| Precipio, Inc. | PRPO | NasdaqCM:PRPO |
| Quest Diagnostics Incorporated | DGX | NYSE:DGX |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| LH | ENZB | OPK | IDXG | PRPO | DGX | ||
| NYSE:LH | OTCPK:ENZB | NasdaqGS:OPK | OTCPK:IDXG | NasdaqCM:PRPO | NYSE:DGX | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | -1.8% | NM- | NM- | NM- | NM- | 5.1% | |
| 3Y CAGR | -22.6% | NM- | NM- | NM- | NM- | -12.1% | |
| Latest Twelve Months | 5.3% | 60.0% | -83.7% | 68.5% | 53.7% | 10.4% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | 19.2% | -19.0% | -6.2% | -16.8% | -100.9% | 22.1% | |
| Prior Fiscal Year | 13.3% | -71.0% | -6.1% | 12.5% | -41.5% | 19.3% | |
| Latest Fiscal Year | 13.1% | -34.8% | -24.6% | 17.9% | -15.8% | 19.3% | |
| Latest Twelve Months | 13.0% | -29.4% | -25.2% | 17.9% | -15.8% | 19.4% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.03x | -0.34x | 1.50x | 0.13x | 0.53x | 2.58x | |
| EV / LTM EBITDA | 15.6x | 1.2x | -6.0x | 0.7x | -3.4x | 13.3x | |
| EV / LTM EBIT | 23.5x | 1.0x | -3.8x | 0.7x | -2.3x | 18.0x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -6.0x | 0.7x | 15.6x | ||||
| Historical EV / LTM EBITDA | 8.0x | 10.3x | 12.7x | ||||
| Selected EV / LTM EBITDA | 10.9x | 11.4x | 12.0x | ||||
| (x) LTM EBITDA | 1,975 | 1,975 | 1,975 | ||||
| (=) Implied Enterprise Value | 21,474 | 22,604 | 23,735 | ||||
| (-) Non-shareholder Claims * | (6,368) | (6,368) | (6,368) | ||||
| (=) Equity Value | 15,106 | 16,236 | 17,367 | ||||
| (/) Shares Outstanding | 111.6 | 111.6 | 111.6 | ||||
| Implied Value Range | 135.32 | 145.44 | 155.56 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 135.32 | 145.44 | 155.56 | 176.96 | |||
| Upside / (Downside) | -23.5% | -17.8% | -12.1% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | LH | ENZB | OPK | IDXG | PRPO | DGX | |
| Enterprise Value | 26,629 | (8) | 1,035 | 8 | 10 | 26,123 | |
| (+) Cash & Short Term Investments | 369 | 40 | 429 | 1 | 1 | 188 | |
| (+) Investments & Other | 168 | 0 | 13 | 0 | 0 | 134 | |
| (-) Debt | (6,585) | (3) | (493) | (6) | (1) | (6,576) | |
| (-) Other Liabilities | (14) | 0 | 0 | 0 | 0 | (114) | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 20,568 | 29 | 983 | 3 | 10 | 19,755 | |
| (/) Shares Outstanding | 83.7 | 52.4 | 793.1 | 4.4 | 1.5 | 111.6 | |
| Implied Stock Price | 245.73 | 0.55 | 1.24 | 0.75 | 6.63 | 176.96 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 245.73 | 0.55 | 1.24 | 0.75 | 6.63 | 176.96 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |